Many biopharmaceutical companies are facing challenges raising cash through traditional equity markets. While venture investment activity saw a slight increase in the first half of 2024 as compared to the equivalent period in...more
9/5/2024
/ Biotechnology ,
Capital Formation ,
Capital Markets ,
Debt Financing ,
Equity Financing ,
Equity Markets ,
Initial Public Offering (IPO) ,
Intellectual Property Agreements ,
IP License ,
Life Sciences ,
Revenue Growth ,
Royalties ,
Sale of Assets ,
Venture Capital